Cargando…

Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients

Detalles Bibliográficos
Autores principales:	Lagler, H, Grabmeier-Pfistershammer, K, Touzeau-Römer, V, Tobudic, S, Rieger, A, Burgmann, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113010/ http://dx.doi.org/10.1186/1758-2652-13-S4-P224

Ejemplares similares

Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals
por: Lagler, Heimo, et al.
Publicado: (2012)

Late versus non-late presentation of HIV/AIDS: an economic impact analysis
por: Grabmeier-Pfistershammer, K, et al.
Publicado: (2010)

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine
por: Zhang, Zhegang, et al.
Publicado: (2022)

Low seroprotection rate for meningococcus serogroup C in the adult HIV-1-infected population in Austria
por: Grabmeier-Pfistershammer, Katharina, et al.
Publicado: (2019)

Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques
por: Liu, Chia-Chyi, et al.
Publicado: (2014)

Safety, tolerability, and antibody response after intradermal vaccination of PFE-BNT in adults who have completed two-doses of Verocell (inactivated vaccine)
por: Chalermphanchai, Nipon, et al.
Publicado: (2022)

Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency
por: Göschl, Lisa, et al.
Publicado: (2022)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Vpr content of HIV-1 virions determines infection of resting peripheral blood CD4(+) lymphocytes
por: Van Nuffel, Anouk, et al.
Publicado: (2013)

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production
por: Herrera-Rodriguez, José, et al.
Publicado: (2019)

ImmunogenIcity of thE PandemRIX A (H1N1) 2009 Influenza vaccine in hemodialysed and renal transplanted patients
por: Hombrouck, A, et al.
Publicado: (2011)

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
por: Gordeychuk, Ilya V., et al.
Publicado: (2023)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
por: Chen, Yaping, et al.
Publicado: (2022)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients †
por: Vajo, Zoltan, et al.
Publicado: (2021)

Phase I clinical trials of safety and immunogenicity of live cultural influenza vaccine vector-flu
por: Nechaeva, Elena A, et al.
Publicado: (2015)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

P12-10. Immunogen utilizing the stable interaction of cytoplasmic tails of HIV-1 envelope and cores
por: Takahashi, H, et al.
Publicado: (2009)

A minimal T-cell immunogen designed to cover HIV-1 specificities associated with control is immunogenic in mice and breaks CTL immunodominance
por: Mothe, B, et al.
Publicado: (2012)

Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems
por: Lin, Chih-Wei, et al.
Publicado: (2014)

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Critical role of calnexin in Nef-mediated inactivation of ABCA1
por: Jennelle, Lucas, et al.
Publicado: (2011)

Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
por: Infimate, DJ L, et al.
Publicado: (2022)

Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level
por: Taylor, Ninon, et al.
Publicado: (2013)

Human Borrelia miyamotoi Infection, Austria
por: Tobudic, Selma, et al.
Publicado: (2020)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

Construction of influenza virosome from influenza A H1N1 PR8
por: Noori, Mehri, et al.
Publicado: (2011)

Safety and immunogenicity of AS03(B) adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
por: Waddington, Claire S, et al.
Publicado: (2010)

Safety of H1N1 and seasonal influenza vaccines in egg allergic patients in British Columbia
por: Leo, Sara H, et al.
Publicado: (2010)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

Transmissibility of pandemic H1N1 and genetically related swine influenza viruses in ferrets
por: Yen, H-L, et al.
Publicado: (2011)

H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study
por: Walker, Woolf T., et al.
Publicado: (2012)

Influenza A (H1N1): the first hit for transfusion-related acute lung injury?
por: Piza, F, et al.
Publicado: (2014)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures
por: Geeraedts, Felix, et al.
Publicado: (2010)

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation
por: Ganneru, Brunda, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_av2ab163kv9errs9inu795mbcn